News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Pharmaceuticals, Inc. Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC


5/16/2013 7:00:19 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

RIDGEFIELD, Conn., May 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced data from two Phase III clinical trials involving two different investigational oncology compounds – afatinib* and nintedanib* – in two distinct patient populations with advanced non-small cell lung cancer (NSCLC). Results from both studies will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at PR Newswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES